Related Experiment Video
Updated: Feb 27, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza
Yasuko Hatta1, David Boltz2, Sally Sarawar3
1FluGen Inc., Madison, WI 53711, USA.
Abstract:
The emergence of highly pathogenic avian influenza H5N1 viruses has heightened global concern about the threat posed by pandemic influenza. To address the need for a highly effective universal influenza vaccine, we developed a novel M2-deficient single replication (M2SR) influenza vaccine virus and previously reported that it provided strong heterosubtypic protection against seasonal influenza viruses in mice. In the current study, we assessed M2SR induced protection against H5N1 influenza in mice and ferrets. Mice were intranasally inoculated with M2SR viruses containing the HA and NA from A/Vietnam/1203/2004 (M2SR H5N1) or A/California/07/2009 (M2SR H1N1). All M2SR vaccinated mice survived lethal challenge with influenza A/Vietnam/1203/2004 (H5N1), whereas 40% of mice vaccinated with recombinant H5 HA and none of the naïve controls survived. M2SR H5N1 provided sterile immunity, whereas low levels of virus were detected in the lungs of some M2SR H1N1 vaccinated mice. In contrast, recombinant H5 HA vaccinated mice and naïve controls showed systemic infection. M2SR H5N1 induced strong serum and mucosal antibody responses (IgG and IgA classes) against H5 HA, with high hemagglutination inhibition (HAI) titers. In contrast, while M2SR H1N1 elicited cross-reactive antibodies recognizing the H5 HA2 stalk region or the neuraminidase, no HAI activity against H5N1 virus was detected after M2SR H1N1 immunization. Both M2SR H5N1 and H1N1 also protected ferrets against lethal challenge with A/Vietnam/1203/2004. A prime-boost regimen provided optimal protection with no virus detected in the respiratory tract or brain after challenge. As in the mouse model, only the M2SR H5N1 vaccine induced HAI antibodies against the challenge virus in ferrets, while the M2SR H1N1 was able to provide protection without the induction of HAI antibodies. In summary, effective protection against highly pathogenic H5N1 influenza virus was provided by both homologous H5N1 M2SR and heterologous H1N1 M2SR demonstrating the cross-protective attributes of the M2SR platform.
Insights
A novel M2-deficient single replication (M2SR) influenza vaccine demonstrated significant protection against highly pathogenic avian influenza H5N1 in mice and ferrets. Both homologous M2SR H5N1 and heterologous M2SR H1N1 vaccines offered cross-protection, highlighting the M2SR platform's versatility for universal influenza vaccines.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Highly pathogenic avian influenza H5N1 poses a significant pandemic threat.
- Existing influenza vaccines require frequent updates due to viral evolution.
- A universal influenza vaccine is needed for broad and durable protection.
Purpose of the Study:
- To evaluate the efficacy of a novel M2-deficient single replication (M2SR) influenza vaccine against H5N1 influenza.
- To assess the protective capabilities of M2SR H5N1 and M2SR H1N1 vaccines in mouse and ferret models.
- To investigate the immune responses induced by M2SR vaccines against H5N1 influenza.
Main Methods:
- Mice and ferrets were vaccinated with M2SR viruses encoding H5N1 or H1N1 hemagglutinin and neuraminidase.
- Vaccinated animals were challenged with a lethal dose of H5N1 influenza virus.
- Humoral immune responses, including hemagglutination inhibition (HAI) titers and antibody classes (IgG, IgA), were measured.
Main Results:
- M2SR H5N1 vaccination conferred sterile immunity and 100% survival in mice challenged with H5N1, outperforming recombinant H5 HA vaccines.
- M2SR H1N1 also provided protection in mice and ferrets against H5N1 challenge, demonstrating cross-protective immunity without high HAI titers.
- Both M2SR H5N1 and M2SR H1N1 vaccines protected ferrets against lethal H5N1 challenge, with prime-boost regimens offering optimal protection.
Conclusions:
- The M2SR influenza vaccine platform effectively protects against highly pathogenic H5N1 influenza.
- Both homologous M2SR H5N1 and heterologous M2SR H1N1 vaccines exhibit cross-protective attributes.
- The M2SR platform shows promise for developing a universal influenza vaccine with broad efficacy.

